Baxter International Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 09/25/2023
Baxter International Inc Stock Forecast and Price Target
Baxter International Inc's most recent price target of $58.00 for 2023 was provided by six renowned analysts over the past few months, with an average prediction of $58.00. If this prediction is correct, Baxter International Inc's stock could rise by 54.67 percent from its current trading price. The potential increase for the stock is $58.00 per share, with a possible range of $51.00 to $85.00. If you're thinking of investing in BAX stock, it might be good to look at its rivals too.
54.67% Upside
Baxter International Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Baxter International Inc has seen a decline in its Price, from $83.41 to $0.00 – a 100.00% decrease. Next year, analysts are expecting Fair Value to reach $122.72 – an increase of 100.00%. Over the next eight years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$552.32 | Buy/Sell | $333.19 | -27.58% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$160.26 | Buy/Sell | $179.95 | 12.63% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$32.98 | Buy/Sell | $44.13 | 59.64% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$105.84 | Buy/Sell | $99.57 | 11.49% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$59.16 | Buy/Sell | $80.99 | 40.30% |
Baxter International Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Baxter International Inc's Revenue has grown from $11.36B to $15.11B – a 33.01% increase. Next year, analysts are expecting Revenue to reach $16.65B – an increase of 10.16%. Over the next eight years, the forecast is for Revenue to grow by 22.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
13
|
$350.67 | Buy/Sell | $384.26 | -7.04% |
| ZTS Stock Forecast | Zoetis Inc | Outperform |
18
|
$177.72 | Buy/Sell | $209.70 | 15.35% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$834.64 | Buy/Sell | $796.73 | -6.31% |
.jpg)
Baxter International Inc Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Baxter International Inc's Dividend per Share has grown by 36.47%, rising from $0.85 to $1.16. For next year, analysts predict Dividend per Share of $1.31, which would mean an increase of 12.93%. Over the next eight years, experts predict that Baxter International Inc's Dividend per Share will grow at a rate of 45.57%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$170.77 | Buy/Sell | $244.18 | 46.98% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$9.71 | Buy/Sell | $13.70 | 39.03% |
| UTHR Stock Forecast | United Therapeutics Corp | Outperform |
12
|
$224.06 | Buy/Sell | $280.69 | 31.66% |
Baxter International Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
Baxter International Inc's Free Cash Flow has decreased In the last three years, from $1.41B to $-1812.00T – a 128693334.59% drop. In the following year, 1 experts forecast Baxter International Inc's Free Cash Flow will decrease by 100.00%, to $2.10B. In 2030, professionals predict that Baxter International Inc's Free Cash Flow will decrease by 100.00%, to $3.01B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent Inc | Hold |
15
|
$45.82 | Buy/Sell | $83.92 | 59.32% |
| IONS Stock Forecast | Ionis Pharmaceuticals Inc | Outperform |
9
|
$42.67 | Buy/Sell | $52.42 | 17.18% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$126.67 | Buy/Sell | $163.67 | 29.47% |
Baxter International Inc Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Baxter International Inc's Net Income has fallen from $1.00B to $-2.42B – a 341.86% decrease. According to 14 prominent analysts, Baxter International Inc's Net Income will fall by 202.07% in the next year, reaching $2.47B. By 2030, professionals believe that Baxter International Inc's Net Income will decrease by 224.69%, reaching $3.02B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NEOG Stock Forecast | Neogen | Hold |
16
|
$19.48 | Buy/Sell | $37.00 | 30.90% |
| CYTK Stock Forecast | Cytokinetics Inc | Outperform |
10
|
$30.00 | Buy/Sell | $62.67 | 100.00% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$8.97 | Buy/Sell | $73.38 | 111.82% |
Baxter International Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Baxter International Inc's EBITDA has seen a drop from $2.61B to $2.37B – a 9.17% decrease. In the next year, analysts believe that EBITDA will reach $4.16B – an increase of 75.93%. For the next eight years, experts predict that Baxter International Inc's EBITDA will grow at a rate of 102.04%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£21.51 | Buy/Sell | £3.79 | -77.96% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$32.82 | Buy/Sell | $79.67 | 137.66% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$32.32 | Buy/Sell | $0.00 | -8.73% |
Baxter International Inc EBIT Forecast for 2023 - 2025 - 2030
Baxter International Inc's EBIT has seen impressive growth In the last two years, rising from $1.82B to $2.09B – a growth of 14.76%. In the next year, analysts believe that EBIT will reach $3.37B – an increase of 61.10%. For the next eight years, the forecast is for EBIT to grow by 88.97%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$45.96 | Buy/Sell | $41.00 | -4.26% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$8.53 | Buy/Sell | $12.60 | 46.54% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$30.06 | Buy/Sell | $35.50 | 13.11% |
Baxter International Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Baxter International Inc has seen a decline in its EPS, from $3.31 to $-4.83 – a 245.92% decrease. According to the 16 analysts polled, in the next year, Baxter International Inc's EPS will fall by 200.83%, reaching $4.87. By 2030, professionals believe that Baxter International Inc's EPS will have decreased by 222.76%, falling to $5.93.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$58.86 | Buy/Sell | $195.43 | 169.28% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$150.96 | Buy/Sell | $170.08 | 15.92% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$59.75 | Buy/Sell | $104.00 | -4.60% |
Site Navigation
.jpg)